|Dr. Laurence James Neil Cooper Ph.D., M.D.||Chief Exec. Officer||N/A||N/A||52|
|Mr. Kevin G. Lafond||Sr. VP of Fin., CFO, Chief Accounting Officer, Treasurer & Corp. Controller||N/A||N/A||61|
|Mr. Caesar J. Belbel||Exec. VP, Chief Legal Officer & Sec.||640.21k||1.62M||57|
|Dr. Francois Lebel M.D.||Chief Medical Officer and Exec. VP of R&D||N/A||N/A||65|
|Dr. David M. Mauney M.D.||Exec. VP, Chief Bus. Officer & Interim COO||N/A||N/A||48|
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexons synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
ZIOPHARM Oncology, Inc.’s ISS Governance QualityScore as of December 1, 2017 is 4. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 2; Compensation: 7.